We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 20 juli 2018

Study on cross-border healthcare: Empowering NCPs to help patients exercise their rights

If you have trouble reading this e-mail read the online version.
European Commission
e-News
20 Jul2018 2018
Health and Food Safety Directorate General
        Twitter Food  icon Twitter             Twitter Health  icon Twitter    
This is the newsletter of DG Health and Food Safety.

The European Commission is committed to personal data protection. Any personal data is processed in line with the Regulation (EC)45/2001.

All personal information processed by the Directorate-General for Health and Food Safety is treated accordingly.

Visit Your Profile to subscribe, unsubscribe or change your options.

For technical problems, please contact sante-webmaster@ec.europa.eu.


RCOA: Recommendations made for anaesthetic care during childbirth

Recommendations made for anaesthetic care during childbirth

The Royal College of Obstetricians and Gynaecologists (RCOG) has published a report into anaesthetic care as part of its national quality improvement programme into stillbirths, neonatal deaths and brain injuries that occur during childbirth.

Read more

Election to RCoA Council 2019: Nominations open

Nominations for election to the Council of The Royal College of Anaesthetists are now open. Council comprises 24 seats, made up of:

  • 20 consultant seats
  • 2 SAS doctor seats and
  • 2 trainee seats.

The vacancies and timetable for 2019 are as follows:

Read more

Nature Reviews Clinical Oncology - Table of Contents alert Volume 15 Issue 8

If you are unable to see the message below, click here to view.
Nature Reviews Clinical Oncology

Advertisement
The Independent and Unbiased Molecular Information Company 

Tumor profiling with Caris Molecular Intelligence® assesses DNA, RNA and proteins to reveal a molecular blueprint in order to guide more precise and personalized treatment decisions. We are committed to ensuring that the right drug gets to the right patient at the right time, without drug recommendation bias.

Your trusted intermediary in molecular profiling

Learn more >
TABLE OF CONTENTS

August 2018 Volume 15, Issue 8

Research Highlights
News & Views
Reviews
Correspondence
 
Advertisement
 

See how droplets are guiding precision medicine

Do you have the tools you need to support clinicians at decisive moments? Liquid biopsy promises a new level of precision in disease profiling and drug resistance monitoring.

See how a promising new technology lets you use this method to its fullest potential to give clinicians insights that can guide personalized cancer treatments and save lives.

 
Advertisement
Nature Reviews Reader Survey

At Nature Reviews we are continually looking for ways to ensure we meet our readers' needs. Your responses to this short survey will give us insight into how our content may be improved.

Get started here.
 
 

Advertisement
nature.com webcasts

Nature Research Custom presents a webcast on: Molecular imaging reveals ONC201 antitumor efficacy and immune stimulation in cancer models

Date: Wednesday, August 15, 2018

Join our live webcast to learn about the benefits of cell culture, xenograft tissue sections and mouse models coupled with imaging in preclinical immuno-oncology trials.

This webcast has been produced on behalf of the sponsor who retains sole responsibility for content 

Register for FREE 

Sponsored by: Perkin Elmer 
 

Research Highlights

 

Avoiding overuse of adjuvant therapies    p469
Diana Romero
doi:10.1038/s41571-018-0054-7

Neoadjuvant FOLFIRINOX improves outcomes    p470
Peter Sidaway
doi:10.1038/s41571-018-0043-x

Genomics reveals distinct gastric cancer subtypes    p470
Peter Sidaway
doi:10.1038/s41571-018-0044-9

New evidence for treatment of ALAL    p470
Peter Sidaway
doi:10.1038/s41571-018-0045-8

Expanding ribociclib use    pp470 - 471
Diana Romero
doi:10.1038/s41571-018-0051-x

Rituximab and ibrutinib synergize in Waldenström macroglobulinaemia    pp470 - 471
David Killock
doi:10.1038/s41571-018-0053-8

Immunoscore provides a more accurate prognosis    p471
Peter Sidaway
doi:10.1038/s41571-018-0050-y

CTCs and benefit from radiotherapy    p472
David Killock
doi:10.1038/s41571-018-0042-y

Cemiplimab effective in cutaneous SCC    p472
Peter Sidaway
doi:10.1038/s41571-018-0056-5

Ivosidenib effective in IDH1-mutant AML    p472
Peter Sidaway
doi:10.1038/s41571-018-0057-4

Nature Reviews Clinical Oncology
JOBS of the week
Faculty Positions at Jiangnan University Wuxi School of Medicine and its Affiliated Hospitals & Clinics
Jiangnan University Wuxi School of Medicine
Fellowship in clinical research, 100% : 50 % clinic and 50% research
CHUV University Hospital of Lausanne
Group Leader in Immuno-Oncology
Gustave Roussy Cancer Campus
Multiple Faculty Positions
The Institute of Health Sciences, Istanbul, Turkey
Faculty Positions in Center for Childhood Cancer and Blood Diseases
Nationwide Children's Hospital, Research Institute
More Science jobs from
Nature Reviews Clinical Oncology
EVENT
International Colloquium on Oncology & Cancer Research
19.09.18
Dubai, UAE
More science events from

News & Views

 

Next-generation sequencing for measuring minimal residual disease in AML    pp473 - 474
Roland B. Walter & Frederick R. Appelbaum
doi:10.1038/s41571-018-0040-0

Novel molecular classifications of DLBCL    pp474 - 476
Sydney Dubois & Fabrice Jardin
doi:10.1038/s41571-018-0041-z

Advertisement
Do you have a career question?

The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud. 

Listen today!
 

Reviews

 

Safety of combining radiotherapy with immune-checkpoint inhibition    pp477 - 494
William L. Hwang, Luke R. G. Pike, Trevor J. Royce, Brandon A. Mahal & Jay S. Loeffler
doi:10.1038/s41571-018-0046-7

The combination of radiotherapy and immune-checkpoint inhibition (ICI) has generated considerable excitement among oncologists, and numerous clinical trials are currently exploring the efficacy of this approach; however, the safety and tolerability of this combination remains incompletely understood. In this Review, the authors describe the available data on safety considerations in patients receiving radiotherapy in combination with ICI.

 

Treatment resistance in urothelial carcinoma: an evolutionary perspective    pp495 - 509
Panagiotis J. Vlachostergios & Bishoy M. Faltas
doi:10.1038/s41571-018-0026-y

Patients with advanced-stage urothelial carcinoma typically receive chemotherapy and might also receive immune-checkpoint inhibitorsfollowing disease progression. However, the majority of patients will ultimately develop resistance to treatment. In this Review, the authors describe the evolutionary mechanisms of treatment resistance in patients with urothelial carcinoma.

 

Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy    pp510 - 527
Jan A. Burger & Susan O'Brien
doi:10.1038/s41571-018-0037-8

In recent years, a number of novel agents have been added to the therapeutic armamentarium for patients with chronic lymphocytic leukaemia (CLL). Herein, Jan A. Burger and Susan O'Brien outline the emerging paradigm of individualized therapy for patients with CLL aimed at exploiting the advantages of these novel agents but also integrating traditional therapies for selected patients.

 

Advertisement
Are you a talented researcher ready for a new leadership role? 

Indiana University's Precision Health Initiative has an ambitious plan to find a cure or an effective treatment for cancer, and your skills could help achieve that goal. 

Find out more.  *ad feature
 

Correspondence

 

Response to proposal for a novel cancer drug pricing model    p528
Toon van der Gronde, Hubertus G. Leufkens & Toine Pieters
doi:10.1038/s41571-018-0062-7

Reply to 'Response to proposal for a novel cancer drug pricing model'    pp528 - 529
Carin A. Uyl-de Groot & Bob Löwenberg
doi:10.1038/s41571-018-0063-6

Advertisement
Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature